Stone Management Segment, by Application to Account Largest Share in Cystoscopy and Ureteroscopy Market during 2025-2031

According to our new research study on "Cystoscopy and Ureteroscopy Market Forecast to 2031 - Global Analysis - by Product Type, Procedure, Technology, Usage Type, And End User," the market was valued at US$ 459.11 million in 2024 to US$ 729.30 million by 2031; the market is expected to register a CAGR of 6.9% during 2025-2031. The cystoscopy and ureteroscopy market growth is attributed to the increasing prevalence of urological diseases and development of technologically advanced and minimally invasive products.

Technological developments in cystoscopy and ureteroscopy techniques have paved the way for the development of highly efficient and effective, and less invasive diagnostic and therapeutic options for urological diseases. Traditional surgical techniques involve larger incisions and longer recovery times. Newly developed technologies aid in more precise and less invasive procedures, leading to faster recovery times with low risks of complications among patients. Moreover, recent developments such as flexible cystoscopy and ureteroscopy, high-definition imaging, and laser technologies have revolutionized urological diagnostics and treatments. Flexible cystoscopes and ureteroscopes aid better accessibility in reaching areas of the urinary tract that might be difficult to reach. High-definition (HD) cameras and digital imaging enhance visualization, which provides more accurate diagnoses and better treatment outcomes. In September 2024, Olympus announced the launch of a new 4K camera head, the CH-S700-08-LB, designed for endoscopic procedures in urology and gynecology. The new component is compatible with the Visera Elite III video system center, which is used in surgical endoscopy. Additionally, in April 2024, Olympus received US clearance for its first single-use ureteroscope system-RenaFlex. The RenaFlex ureteroscope is designed to facilitate access and visualization into the urinary tract, aiding in the diagnosis and treatment of urinary diseases and disorders, such as kidney stones. Further, laser technology has made it possible to treat conditions such as kidney stones more effectively, owing to the ability of laser beams to break down stones with minimal disruption to surrounding tissues, thus reducing the need for traditional surgical methods.

In September 2022, Photocure ASA supported the global launch activities for the innovative Blue Light Cystoscopy (BLC) system, which utilizes the new POWER LED SAPHIRA light source from KARL STORZ. The system is designed to work with Photocure's Hexvix system for the detection of bladder cancer. In Europe, the photodynamic diagnostics (PDD) system incorporated with POWER LED SAPHIRA was unveiled during an E-Masterclass Webinar arranged by both companies in September 2022. Such technological advancements have reduced procedural costs over time. Hence, cystoscopy and ureteroscopy procedures have become cheaper and accessible to a larger population. Thus, the development and launch of technologically advanced products and minimally invasive procedures favor the cystoscopy and ureteroscopy market progression.

Based on Product type, the cystoscopy and ureteroscopy market is bifurcated into cystoscope and ureteroscope. The cystoscope segment held a larger cystoscopy and ureteroscopy market share in 2024, and is expected to register a higher CAGR during 2025-2031. Cystoscopes are essential tools for examining the bladder and urinary tract, and these instruments have undergone significant technological advancements in recent years. Modern cystoscopes feature high-definition imaging, 3D visualization, and fluorescence technologies, which enhance their diagnostic precision. Moreover, innovations such as flexible, miniaturized designs and improved light sources contribute to better access to hard-to-reach areas along with greater patient comfort. Additionally, the integration of artificial intelligence aids in the early detection of abnormalities, further improving diagnostic accuracy.

Several companies are launching new and improved cystoscope models. For example, in September 2022, Photocure ASA announced the global launch of its new and improved Blue Light Cystoscopy (BLC) system, designed to be used with its Hexvix system for detecting bladder cancer. Similarly, in May 2021, the FDA granted clearance to UroViu Corporation to market Uro-G, a flexible, portable, single-use cystoscope. The self-contained Uro-G device features a fully deflectable tip, providing urologists with the flexibility to use it for diagnostic or interventional procedures in any room in their clinics. Karl Storz and Olympus Corporation offer cutting-edge flexible cystoscopes with superior imaging capabilities. Fujifilm has introduced systems integrated with advanced diagnostic features. Similarly, Stryker focuses on minimally invasive solutions. Medtronic continues to develop cystoscopes equipped with smart technology, ensuring better patient outcomes. These innovations are shaping the future of urological diagnostics, making procedures more effective and less invasive.

Based on application, the market is segmented into stone management, bladder cancer, benign prostatic hyperplasia (BPH), and others. The stone management segment held the largest cystoscopy and ureteroscopy market share in 2024, and the same segment is estimated to register the higher CAGR during 2025-2031. Cystoscopy plays a crucial role in detecting and managing urinary stones, especially those located in the bladder or lower urinary tract. By utilizing a cystoscope-a thin, flexible tube-physicians can directly visualize the stones, and assess their size and location, in turn making decisions about the selection of appropriate treatments such as stone extraction or laser lithotripsy. Recent technological advancements in cystoscopy have significantly improved the detection and management of urinary stones. High-definition (HD) and digital cystoscopes provide clearer and more detailed images, making it easier to identify small or difficult-to-detect stones. In addition, innovations such as laser cystoscopy enable the use of laser energy during procedures to fragment and remove stones, thereby minimizing the need for more invasive surgeries. The integration of NBI and fluorescence imaging also enhances the visualization of bladder stones, offering better contrast compared to traditional white-light cystoscopy.

Similarly, ureteroscopy aids in stone management by allowing direct visualization and removal of stones from the urinary tract using minimally invasive techniques. It reduces recovery time, minimizes complications, and provides effective treatment options, such as laser lithotripsy for stone fragmentation and extraction.

Several leading companies provide cystoscopes and ureteroscope for stone management. Olympus Corporation offers digital and laser systems for stone removal; Karl Storz GmbH is also known for its high-quality rigid and flexible cystoscopes. Pentax Medical produces advanced imaging cystoscopes, and Stryker provides state-of-the-art digital cystoscopes and laser devices. Richard Wolf specializes in high-resolution cystoscopes and laser lithotripsy technology.

Olympus Corp, Karl Storz SE & Co KG, Richard Wolf GmbH, Ambu A/S, PENTAX Medical, Advin Health Care Pvt Ltd, Coloplast Corp, Cook Medical Holdings LLC, Electronics Services Centre (ESC Medicams), Stryker Corp, Rudra Surgicals, Laborie, Teleflex Inc, NIDHI MEDITECH SYSTEMS, Pioneer Healthcare Technologies, Boston Scientific Corp, Ottomed Endoscopy, Becton Dickinson and Co, SCH